Researching the genetic basis of hypertrophic cardiomyopathy in London with the ACS Work Visit GrantMarion van Vugt, Postdoctoral Researcher at Amsterdam UMC, visited University College London (UCL) with the support of the ACS Work Visit Grant. There, she investigated the role of rare and intermediate-effect genetic variants in hypertrophic cardiomyopathy — and laid the foundation for new collaborations between the two institutes.
Bone marrow link: Amsterdam UMC study suggests anti‑inflammatory effects of semaglutideSemaglutide, the GLP-1 receptor agonist known as Ozempic and Wegovy, is associated with fewer inflammatory monocytes and reduced inflammatory activity in the bone marrow of people with type 2 diabetes. Researchers from Amsterdam UMC and Amsterdam Cardiovascular Sciences report this in an exploratory first-in-human study published in the European Heart Journal, offering a potential explanation for the cardiovascular benefits of GLP-1 therapies.
